Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

نویسندگان

  • Salpie Nowinski
  • Aida Santaolalla
  • Ben O'Leary
  • Massimo Loda
  • Ayesha Mirchandani
  • Mark Emberton
  • Mieke Van Hemelrijck
  • Anita Grigoriadis
چکیده

Novel approaches for classification, including molecular features, are needed to direct therapy for men with low-grade prostate cancer (PCa), especially men on active surveillance. Risk alleles identified from genome-wide association studies (GWAS) could improve prognostication. Those risk alleles that coincided with genes and somatic copy number aberrations associated with progression of PCa were selected as the most relevant for prognostication. In a systematic literature review, a total of 698 studies were collated. Fifty-three unique SNPs residing in 29 genomic regions, including 8q24, 10q11 and 19q13, were associated with PCa progression. Functional studies implicated 21 of these single nucleotide polymorphisms (SNPs) as modulating the expression of genes in the androgen receptor pathway and several other oncogenes. In particular, 8q24, encompassing MYC, harbours a high density of SNPs conferring unfavourable pathological characteristics in low-grade PCa, while a copy number gain of MYC in low-grade PCa was associated with prostate-specific antigen recurrence after radical prostatectomy. By combining GWAS data with gene expression and structural rearrangements, risk alleles were identified that could provide a new basis for developing a prognostication tool to guide therapy for men with early prostate cancer.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Blood-Based Biomarkers of Aggressive Prostate Cancer

PURPOSE Prostate cancer is a bimodal disease with aggressive and indolent forms. Current prostate-specific-antigen testing and digital rectal examination screening provide ambiguous results leading to both under-and over-treatment. Accurate, consistent diagnosis is crucial to risk-stratify patients and facilitate clinical decision making as to treatment versus active surveillance. Diagnosis is ...

متن کامل

The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.

PURPOSE Gleason score (GS) 7 prostate cancer is a heterogeneous disease with different clinical behavior. We sought to identify genetic biomarkers that may predict the aggressiveness of GS 7 diseases. EXPERIMENTAL DESIGN We genotyped 72 prostate cancer susceptibility SNPs identified in genome-wide association studies in 1,827 white men with histologically confirmed prostate adenocarcinoma. SN...

متن کامل

Diagnostic and prognostic value of molecular cytogenetic analyses of sextant biopsies from prostate cancer suspects.

Prostate cancer is one of the most prevalent human malignancies and a common cause of cancer-related morbidity and mortality. The great variation in clinical behavior of these tumors creates a major dilemma in the treatment-decision process, since not all men with microscopic carcinoma require aggressive radical therapy. Given the present-day absence of a reliable way to predict which cancers w...

متن کامل

COUP-TFII, a prognostic marker and therapeutic target for prostate cancer.

T he absence of a biomarker to predict the aggressiveness of prostate cancer patients is the major obstacle in deciding which prostate cancer patient should be treated. In this report, we show that COUP transcription factor II (COUP-TFII), a member of the nuclear receptor superfamily, antagonizes the transforming growth factor (TGF)-b-induced growth barrier to facilitate tumor metastasis and pr...

متن کامل

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis

Background: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. Methods: MEDLINE, Web of Science and the Cochrane librar...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Oncotarget

دوره 9 16  شماره 

صفحات  -

تاریخ انتشار 2018